Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

563

HTML

2620

Tables (1-2)

191

Sum=3374

Jan 7, 2006 (publication date) through Feb 9, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jan 7, 2006; 12(1): 110-113
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.110

Table 1 Some major clinical and laboratory parameters in patients with ulcerative colitis and control subjects (mean ± SE)

Parameters	UC patients, n = 44	Controls, n = 44
Females/males	19/25	24/20
CRP (mg/L)	12.2 ± 4.5	2.6 ± 0.5
Albumin (g/L)	44.6 ± 0.7	50.2 ± 0.8
Iron (µmol/L)	16.1 ± 1.2	23.7 ± 1.6
Hb (g/dL)	131.3 ± 2.5	159 ± 1.2
MCV (L)	86.2 ± 1.2	94.8 ± 2.5
WBC (G/L )	7.6 ± 0.4	9.2 ± 0.6
BMI (kg/m²)	24.6 ± 0.6	24.1 ± 0.5
PLT (G/L)	298.5 ± 13.5	228.3 ± 10.4
Both ileum and colon localization	5/44 (11.4%)
Rectosigmoid
localization only	8/44 (18.2%)
Colon localization	31/44 (70.4%)

Table 2 Plasma carnitine ester profiles in ulcerative colitis patients and controls (µmol/L, mean ± SE)

	UC patients, n = 44	Controls, n = 44
Free carnitine (C0)	31.595 ± 1.454	31.431 ± 1.042
Short-chain acylcarnitines
Acetylcarnitine (C2)	9.164 ± 0.426	10.179 ± 0.461
Propionylcarnitine (C3)	0.331 ± 0.019^a	0.392 ± 0.017
Butyrylcarnitine (C4)	0.219 ± 0.014^a	0.265 ± 0.012
Isovalerylcarnitine (C5)	0.111 ± 0.008^a	0.134 ± 0.008
Tiglylcarnitine (C5:1)	0.030 ± 0.004	0.033 ± 0.002
Medium-chain acylcarnitines
Hexanoylcarnitine (C6)	0.071 ± 0.006	0.081 ± 0.005
Octenoylcarnitine (C8)	0.147 ± 0.009^a	0.114 ± 0.008
Octenoylcarnitine (C8:1)	0.064 ± 0.005	0.062 ± 0.007
Decanoylcarnitine (C10)	0.180 ± 0.012^a	0.137 ± 0.008
Cecenoylcarnitine (C10:1)	0.113 ± 0.006	0.104 ± 0.008
Lauroylcarnitine (C12)	0.054 ± 0.003	0.050 ± 0.003
Long-chain acylcarnitines
Myristoylcarnitine (C14)	0.026 ± 0.001	0.024 ± 0.001
Myristoleylcarnitine (C14:1)	0.048 ± 0.003^a	0.039 ± 0.003
Palmitoylcarnitine (C16)	0.128 ± 0.006^a	0.109 ± 0.004
Palmitoylcarnitine (C16:1)	0.042 ± 0.003^a	0.031 ± 0.002
Stearoylcarnitine (C18)	0.085 ± 0.003	0.079 ±0.003
Oleylcarnitine (C18:1)	0.183 ± 0.007^a	0.163 ± 0.007
Hydroxymyristoylcarnitine (C14OH)	0.007 ± 0.001	0.006 ± 0.001
Hydroxypalmitoylcarnitine (C16OH)	0.026 ± 0.002	0.023 ± 0.001
Hydroxypalmitoleylcarnitine (C16:1OH)	0.033 ± 0.002	0.029 ± 0.002
Hydroxyoleylcarnitine (C18:1OH)	0.018 ± 0.002^a	0.012 ± 0.001

^aP < 0.05 vs controls.

Citation: Bene J, Komlósi K, Havasi V, Talián G, Gasztonyi B, Horváth K, Mózsik G, Hunyady B, Melegh B, Figler M. Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis. World J Gastroenterol 2006; 12(1): 110-113
URL: https://www.wjgnet.com/1007-9327/full/v12/i1/110.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i1.110